PL438135A1 - Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych - Google Patents

Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Info

Publication number
PL438135A1
PL438135A1 PL438135A PL43813521A PL438135A1 PL 438135 A1 PL438135 A1 PL 438135A1 PL 438135 A PL438135 A PL 438135A PL 43813521 A PL43813521 A PL 43813521A PL 438135 A1 PL438135 A1 PL 438135A1
Authority
PL
Poland
Prior art keywords
glucose
prevention
treatment
autoimmune diseases
methotrexate conjugate
Prior art date
Application number
PL438135A
Other languages
English (en)
Other versions
PL243573B1 (pl
Inventor
Siddarth AGRAWAL
Marta WOŹNIAK
Sebastian MAKUCH
Wiesław Szeja
Gabriela PASTUCH-GAWOŁEK
Monika Krawczyk
Jerzy Wiśniewski
Andrzej Gamian
Piotr ZIÓŁKOWSKI
Grzegorz Mazur
Original Assignee
Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu filed Critical Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority to PL438135A priority Critical patent/PL243573B1/pl
Priority to PCT/PL2022/050037 priority patent/WO2022260546A1/en
Priority to PL22820644.7T priority patent/PL4351590T3/pl
Priority to EP22820644.7A priority patent/EP4351590B1/en
Publication of PL438135A1 publication Critical patent/PL438135A1/pl
Publication of PL243573B1 publication Critical patent/PL243573B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych, w szczególności reumatoidalnego zapalenia stawów lub łuszczycy.
PL438135A 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych PL243573B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych
PCT/PL2022/050037 WO2022260546A1 (en) 2021-06-11 2022-06-13 A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases
PL22820644.7T PL4351590T3 (pl) 2021-06-11 2022-06-13 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych
EP22820644.7A EP4351590B1 (en) 2021-06-11 2022-06-13 A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Publications (2)

Publication Number Publication Date
PL438135A1 true PL438135A1 (pl) 2022-12-12
PL243573B1 PL243573B1 (pl) 2023-09-11

Family

ID=84425365

Family Applications (2)

Application Number Title Priority Date Filing Date
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych
PL22820644.7T PL4351590T3 (pl) 2021-06-11 2022-06-13 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22820644.7T PL4351590T3 (pl) 2021-06-11 2022-06-13 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Country Status (3)

Country Link
EP (1) EP4351590B1 (pl)
PL (2) PL243573B1 (pl)
WO (1) WO2022260546A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL243572B1 (pl) * 2021-06-11 2023-09-11 Univ Medyczny Im Piastow Slaskich We Wroclawiu Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200536861A (en) * 2004-04-02 2005-11-16 Denki Kagaku Kogyo Kk Hyaluronic acid/methotrexate compound
PL242529B1 (pl) * 2018-08-20 2023-03-06 Univ Medyczny Im Piastow Slaskich We Wroclawiu Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania

Also Published As

Publication number Publication date
EP4351590C0 (en) 2025-12-10
EP4351590B1 (en) 2025-12-10
EP4351590A4 (en) 2025-02-26
EP4351590A1 (en) 2024-04-17
PL243573B1 (pl) 2023-09-11
PL4351590T3 (pl) 2026-04-27
WO2022260546A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JOP20200210A1 (ar) أجسام مضادة مساعدة لـ pd-1 واستخداماتها
CR20220332A (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
WO2020023978A3 (en) Systems and methods for treating memory impairment
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EA202092225A1 (ru) Соединения и их применение
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.
ES2380951T9 (es) Diaril-purinas, -azapurinas y -desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
BR112022024382A2 (pt) Formas sólidas de pralsetinibe
EA202191489A1 (ru) Способы лечения миелопролиферативных расстройств
CL2023002698A1 (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
MX2024009868A (es) Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
MX2026002369A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
JOP20240060A1 (ar) سلسلة جزيئات متجاورة مشتقة من-tn3 نوعي لـ cd40l للاستخدام في العلاج أو الوقاية من التهاب المفاصل الروماتويدي
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
CR20240365A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
MX2022013607A (es) Derivados de la pirimidina-4(3h)-ona como antagonistas de trpv4.
MX2019008782A (es) Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.
FR3108031B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
GEAP202315302A (en) METHOD FOR TREATING TNFα-RELATED DISEASE
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
PL434198A1 (pl) Związki do leczenia lub diagnostyki COVID-19